A differentiated upstream approach. Many therapeutic agents for the treatment of non-alcoholic steatohepatitis in clinical development mechanistically act on the downstream consequences of hepatosteatosis, such as inflammation and fibrosis. We have developed small molecule inhibitors of fatty acid synthase (FASN), a key enzyme in the de novo lipogenesis pathway that catalyzes the final step in fatty acid production prior to TG synthesis. Elevated de novo lipogenesis can contribute to early points in the pathogenesis of non-alcoholic steatohepatitis via excessive TG synthesis and subsequent deposition in the liver causing steatosis. FT-8225, a preclinical investigational agent, is a selective and liver targeted fatty acid synthase inhibitor. Our hypothesis is that by selectively inhibiting fatty acid synthase in the liver, the rate of new fat production or de novo lipogenesis would be reduced, thereby reducing lipid accumulation in the liver and potentially reducing the downstream consequences of cellular damage, inflammation and fibrosis that characterizes the pathology of non-alcoholic steatohepatitis. 300 North Beacon Street, Suite 501 Watertown, MA 02472 617.679.1970 twitter linkedin instagram facebook glassdoor Privacy Policy Terms of Use © 2021 ALL RIGHTS RESERVED

OUR PROGRAMS Metastatic Castration-Resistant Prostate Cancer (mCRPC) FT-7051 Explore For individuals at higher risk of getting prostate cancer, healthcare professionals might recommend one of two screening methods: a prostate-specific antigen (PSA) blood test or a digital rectal exam. Screening tests are used to look for possible signs of prostate cancer.3 Until recently, there has been little innovation in potential prostate cancer treatments. Therapies that reduce androgen levels or block the binding of androgen to its receptor are common treatments. But studies have shown that approximately 20% to 40% of metastatic castration-resistant prostate cancer patients demonstrate primary resistance to such therapies, and virtually all patients who demonstrate initial clinical responses eventually acquire resistance.4 Some instances of prostate cancer progress over many years, but too often there are patients who fight very aggressive cases. We continue to learn from the community that this isn’t widely understood. My father-in-law Josep passed less than two years after diagnosis. Seared in my memory is seeing him travel by subway with his three sons to enjoy a Barcelona soccer match in the famous Camp Nou stadium. That memory always reinforces to me the importance of keeping the whole patient, not just the disease, in mind as we pursue therapies and engage with people who are living with the illness. Sylvie G. executive director, translational science 300 North Beacon Street, Suite 501 Watertown, MA 02472 617.679.1970 twitter linkedin instagram facebook glassdoor Privacy Policy Terms of Use © 2021 ALL RIGHTS RESERVED